GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acrux Ltd (OTCPK:ARUXF) » Definitions » Total Liabilities

Acrux (ARUXF) Total Liabilities : $2.78 Mil (As of Dec. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Acrux Total Liabilities?

Acrux's Total Liabilities for the quarter that ended in Dec. 2024 was $2.78 Mil.

Acrux's quarterly Total Liabilities declined from Dec. 2023 ($4.27 Mil) to Jun. 2024 ($3.78 Mil) and declined from Jun. 2024 ($3.78 Mil) to Dec. 2024 ($2.78 Mil).

Acrux's annual Total Liabilities declined from Jun. 2022 ($3.66 Mil) to Jun. 2023 ($3.08 Mil) but then increased from Jun. 2023 ($3.08 Mil) to Jun. 2024 ($3.78 Mil).

Acrux Total Liabilities Historical Data

The historical data trend for Acrux's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acrux Total Liabilities Chart

Acrux Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.44 3.71 3.66 3.08 3.78

Acrux Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.96 3.08 4.27 3.78 2.78

Acrux Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Acrux's Total Liabilities for the fiscal year that ended in Jun. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=2.471+(1.278+-3.0878077872387E-16
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0.027+0)
=3.78

Total Liabilities=Total Assets (A: Jun. 2024 )-Total Equity (A: Jun. 2024 )
=5.952-2.175
=3.78

Acrux's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=1.609+(1.144+0.022
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=2.78

Total Liabilities=Total Assets (Q: Dec. 2024 )-Total Equity (Q: Dec. 2024 )
=4.934-2.159
=2.78

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Acrux Total Liabilities Related Terms

Thank you for viewing the detailed overview of Acrux's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Acrux Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acrux Ltd (OTCPK:ARUXF) » Definitions » Total Liabilities
Comparable Companies
ASX:RCE ASX:CHM ASX:1AI ASX:BGT ASX:CMB ASX:ZLD ASX:NSB ASX:1AD ASX:IXC ASX:PAB VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
FJY:Germany ACR:Australia
Address
103-113 Stanley Street, West Melbourne, Melbourne, VIC, AUS, 3003
Website
https://www.acrux.com.au
Acrux Ltd is a pharmaceutical company dedicated to developing and commercializing generic transdermal and topical prescription pharmaceuticals. The group is formulating and developing a range of topical generic products by leveraging its skilled workforce, on-site laboratories, GMP manufacturing suite, and technical, clinical, and commercial experience to bring affordable products to market. Geographically, it has a presence in Australia; the United States; Europe, and other countries. The firm operates in a single segment and derives revenue from developing and commercializing pharmaceutical products that administer drugs topically. Its product pipeline products include Lenzetto, Evamist, Testosterone Topical Solution, and among others.